Cytokine units of immunoregulation of diabetic-associated osteoarthritis

Joint damage in patients with diabetes mellitus (DM) is a common complication and is associated with the induction of metabolic inflammation against the background of increased catabolic processes in various joint structures. The aim of our study was a study of the levels of proinflammatory cytokines in the serum of patients with diabetes-associated osteoarthritis. Materials and methods. We examined 118 patients, who were divided into groups according to the type of diabetes, the presence and severity of diabetic arthropathy. The content of IL-1α, IL-6, S IL-6-R receptors, TNF-α, osteoprotegerin (soluble TNF-α receptor) in blood serum was determined by enzyme-linked immunosorbent assay. Results Among the examined patients, diabetic arthropathy was diagnosed in more than 70% of patients with diabetes of both types. In patients with diabetic arthropathy, levels of TNF-α (44.5% in type 1 diabetes, 42.9% in type 2 diabetes) and its soluble osteoprotegerin receptor (74.1% in type 1 diabetes) were significantly increased. Type 2 diabetes by 52.9%, as well as IL-6 (with type 1 diabetes by 52.1%, with type 2 diabetes by 64.4%) There is a direct correlation between the severity of joint damage and the level of TNF-α , osteoprotegerin and IL-6. For IL-1, S IL-6-R receptors such changes were not detected.The chances of detecting arthropathy with increasing levels of TNF-a in type 1 diabetes increase by 1.7 (OR = 1, 70 ; DI 1,19-2,44) times, at D 2 type - 1.8 times (OR = 1.78; DI 1.21-1.2.61), with an increase in IL-6 in type 1 diabetes increase by 1.5 (OR = 1.47; DI 1.08 -1.98) times, with type 2 diabetes - 1.3 times (OR = 1.34; DI 1.03-1.74), with elevated levels of osteoprotegerin diabetic arthropathy is 2.3 times more common in patients with type 1 diabetes (OR = 2.33; DI 1.42-3.82) and 1.6 times in patients with type 2 diabetes (SHR = 1.55; DI 1.14-2.10). Conclusions. Thus, TNF-α, osteoprotegerin, and IL-6 may serve as markers of the presence and progression of joint damage in patients with diabetes.